Electrochemiluminescent aptamer-sensor for alpha synuclein oligomer based on a metal-organic framework

Amyloid detection in neurodegenerative diseases using MOFs

Neurodegenerative diseases (amyloid diseases such as Alzheimer's and Parkinson's), stemming from protein misfolding and aggregation, encompass a spectrum of disorders with severe systemic implications. Timely detection is pivotal in managing these diseases owing to their significant impact on organ function and high mortality rates. The diverse array of amyloid disorders, spanning localized and systemic manifestations, underscores the complexity of these conditions and highlights the need for advanced detection methods. Traditional approaches have focused on identifying biomarkers using imaging techniques (PET and MRI) or invasive procedures. However, recent efforts have focused on the use of metal-organic frameworks (MOFs), a versatile class of materials known for their unique properties, in revolutionizing amyloid disease detection. The high porosity, customizable structures, and biocompatibility of MOFs enable their integration with biomolecules, laying the groundwork for highly sensitive and specific biosensors. These sensors have been employed using electrochemical and photophysical techniques that target amyloid species under neurodegenerative conditions. The adaptability of MOFs allows for the precise detection and quantification of amyloid proteins, offering potential advancements in early diagnosis and disease management. This review article delves into how MOFs contribute to detecting amyloid diseases by categorizing their uses based on different sensing methods, such as electrochemical (EC), electrochemiluminescence (ECL), fluorescence, Förster resonance energy transfer (FRET), up-conversion luminescence resonance energy transfer (ULRET), and photoelectrochemical (PEC) sensing. The drawbacks of MOF biosensors and the challenges encountered in the field are also briefly explored from our perspective.

Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases

The use of nanomaterials in medicine offers multiple opportunities to address neurodegenerative disorders such as Alzheimer's and Parkinson's disease. These diseases are a significant burden for society and the health system, affecting millions of people worldwide without sensitive and selective diagnostic methodologies or effective treatments to stop their progression. In this sense, the use of gold nanoparticles is a promising tool due to their unique properties at the nanometric level. They can be functionalized with specific molecules to selectively target pathological proteins such as Tau and α-synuclein for Alzheimer's and Parkinson's disease, respectively. Additionally, these proteins are used as diagnostic biomarkers, wherein gold nanoparticles play a key role in enhancing their signal, even at the low concentrations present in biological samples such as blood or cerebrospinal fluid, thus enabling an early and accurate diagnosis. On the other hand, gold nanoparticles act as drug delivery platforms, bringing therapeutic agents directly into the brain, improving treatment efficiency and precision, and reducing side effects in healthy tissues. However, despite the exciting potential of gold nanoparticles, it is crucial to address the challenges and issues associated with their use in the medical field before they can be widely applied in clinical settings. It is critical to ensure the safety and biocompatibility of these nanomaterials in the context of the central nervous system. Therefore, rigorous preclinical and clinical studies are needed to assess the efficacy and feasibility of these strategies in patients. Since there is scarce and sometimes contradictory literature about their use in this context, the main aim of this review is to discuss and analyze the current state-of-the-art of gold nanoparticles in relation to delivery, diagnosis, and therapy for Alzheimer's and Parkinson's disease, as well as recent research about their use in preclinical, clinical, and emerging research areas.

Sensor-integrated brain-on-a-chip platforms: Improving the predictive validity in neurodegenerative research

Affecting millions of individuals worldwide, neurodegenerative diseases (NDDs) pose a significant and growing health concern in people over the age of 60 years. Contributing to this trend are the steady increase in the aging population coupled with a persistent lack of disease-altering treatment strategies targeting NDDs. The absence of efficient therapeutics can be attributed to high failure rates in clinical trials and the ineptness of animal models in preceding preclinical studies. To that end, in recent years, significant research effort has been dedicated to the development of human cell-based preclinical disease models characterized by a higher degree of predictive validity. However, a key requirement of any in vitro model constitutes the precise knowledge and replication of the target tissues' (patho-)physiological microenvironment. Herein, microphysiological systems have demonstrated superiority over conventional static 2D/3D in vitro cell culture systems, as they allow for the emulation and continuous monitoring of the onset, progression, and remission of disease-associated phenotypes. This review provides an overview of recent advances in the field of NDD research using organ-on-a-chip platforms. Specific focus is directed toward non-invasive sensing strategies encompassing electrical, electrochemical, and optical sensors. Additionally, promising on- and integrable off-chip sensing strategies targeting key analytes in NDDs will be presented and discussed in detail.

A review on the new age methodologies for early detection of Alzheimer's and Parkinson's disease

BACKGROUNDS

Neurodegenerative diseases (NDDs) such as Alzheimer's (AD) and Parkinson's (PD) are often diagnosed late, impeding effective treatment; therefore, early detection is imperative. Modern methodologies can serve a pivotal role in fulfilling the crucial need for timely detection and intervention in this context.

OBJECTIVES

Evaluate early detection's significance and summarize key technologies (biomarkers, neuroimaging, AI/ML, genetics, digital health) for enhanced diagnostic strategies in AD and PD.

METHODS

This study employs a focused descriptive review approach, encompassing analysis of peer-reviewed articles and clinical trials from existing literature, to provide a nuanced exploration of the subject matter.

FINDINGS

This review underscores the efficacy of non-invasive biomarkers, biosensors and emerging promising technologies for advancing early diagnosis of AD and PD.

CONCLUSION

The landscape of early NDD detection has been reshaped by technology, yet challenges persist, encompassing the domains of validation and ethics. A collaborative effort between medical professionals, researchers and technologists is imperative to effectively address and combat NDDs.

Electrochemical chiral sensor for levofloxacin detection base on Cu/Fe-BTC amplification

The key to developing sensors for chiral drug determination is to exclude interference from enantiomers. In this study, metal-organic frameworks (MOFs) and molecularly imprinted polymer (MIP) were introduced to prepare a chiral sensor for levofloxacin detection. The MIP was electropolymerised on the surface of the Cu/Fe-benzene-1,3,5-tricarboxylate MOF (Cu/Fe-BTC)-modified Au electrode using levofloxacin as a template molecule. After eluting the levofloxacin, a chiral sensor with recognition sites for levofloxacin was obtained. With this site as a switch, a novel method for detecting levofloxacin was established. Because of the enhanced recognition effect, the sensor can effectively exclude the enantiomeric interference of d-ofloxacin. Moreover, Cu/Fe-BTC can effectively amplify the current response signal and improve the sensitivity of the sensor. The linear range of the sensor was 5 to 4000 × 10-11 mol L-1, and the detection limit was 2.07 × 10-11 mol L-1. When applied to detecting levofloxacin in actual samples, the sensor showed a 92.7-109.8% recovery.

Metal-Organic Frameworks-Based Nanoplatforms for the Theranostic Applications of Neurological Diseases

Neurological diseases are the foremost cause of disability and the second leading cause of death worldwide. Owing to the special microenvironment of neural tissues and biological characteristics of neural cells, a considerable number of neurological disorders are currently incurable. In the past few years, the development of nanoplatforms based on metal-organic frameworks (MOFs) has broadened opportunities for offering sensitive diagnosis/monitoring and effective therapy of neurology-related diseases. In this article, the obstacles for neurotherapeutics, including delayed diagnosis and misdiagnosis, the existence of blood brain barrier (BBB), off-target treatment, irrepressible inflammatory storm/oxidative stress, and irreversible nerve cell death are summarized. Correspondingly, MOFs-based diagnostic/monitoring strategies such as neuroimaging and biosensors (electrochemistry, fluorometry, colorimetry, electrochemiluminescence, etc.) and MOFs-based therapeutic strategies including higher BBB permeability, targeting specific lesion sites, attenuation of neuroinflammation/oxidative stress as well as regeneration of nerve cells, are extensively highlighted for the management of neurological diseases. Finally, the challenges of the present research from perspective of clinical translation are discussed, hoping to facilitate interdisciplinary studies at the intersections between MOFs-based nanoplatforms and neurotheranostics.

A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson's disease

Parkinson's disease is a health-threatening neurodegenerative disease of the elderly with clinical manifestations of motor and non-motor deficits such as tremor palsy and loss of smell. Alpha-synuclein (α-Syn) is the pathological basis of PD, it can abnormally aggregate into insoluble forms such as oligomers, fibrils, and plaques, causing degeneration of nigrostriatal dopaminergic neurons in the substantia nigra in the patient's brain and the formation of Lewy bodies (LBs) and Lewy neuritis (LN) inclusions. As a result, achieving α-Syn aggregate detection in the early stages of PD can effectively stop or delay the progression of the disease. In this paper, we provide a brief overview and analysis of the molecular structures and α-Syn in vivo and in vitro detection methods, such as mass spectrometry, antigen-antibody recognition, electrochemical sensors, and imaging techniques, intending to provide more technological support for detecting α-Syn early in the disease and intervening in the progression of Parkinson's disease.

Metal-Organic Frameworks as Sensors for Human Amyloid Diseases

Metal-organic frameworks (MOFs) are versatile compounds with emergent applications in the fabrication of biosensors for amyloid diseases. They hold great potential in biospecimen protection and unprecedented probing capabilities for optical and redox receptors. In this Review, we summarize the main methodologies employed in the fabrication of MOF-based sensors for amyloid diseases and collect all available data in the literature related to their performance (detection range, limit of detection, recovery, time of analysis, among other parameters). Nowadays, MOF sensors have evolved to a point where they can, in some cases, outperform technologies employed in the detection of several amyloid biomarkers (amyloid β peptide, α-synuclein, insulin, procalcitonin, and prolactin) present in biological fluids, such as cerebrospinal fluid and blood. A special emphasis has been given by researchers on Alzheimer's disease monitoring to the detriment of other amyloidosis that are underexploited despite their societal relevance (e.g., Parkinson's disease). There are still important obstacles to overcome in order to selectively detect the various peptide isoforms and soluble amyloid species associated with Alzheimer's disease. Furthermore, MOF contrast agents for imaging peptide soluble oligomers in living humans are also scarce (if not nonexistent), and action in this direction is unquestionably required to clarify the contentious link between the amyloidogenic species and the disease, guiding research toward the most promising therapeutic strategies.

A FRET-based aptasensor for the detection of α-synuclein oligomers as biomarkers of Parkinson's disease

Soluble oligomers of α-synuclein (α-syn) are known to be responsible for neuronal death in the early stages of Parkinson's disease (PD). Thus, the development of a simple, rapid, and inexpensive method for the detection of α-syn oligomers can help PD diagnosis before irreversible damage to the brain tissue occurs. The present study is aimed at developing a FRET-based aptasensor for the selective and sensitive detection of α-syn oligomers. Herein, FAM-labeled aptamer adsorption on graphene oxide (GO) resulted in fluorescence quenching of FAM. The binding of α-syn oligomers to the aptamer led to the recovery of the fluorescence intensity. Under optimized conditions, the developed biosensor showed two linear response ranges from 10-100 nM and 250 nM to 2 μM in α-syn oligomer detection. The limit of detection (LOD) and limit of quantification (LOQ) were calculated to be 6.3 nM and 19.3 nM, respectively. Furthermore, the performance of the sensing platform in the detection of the target analyte in biological matrices was demonstrated by the assay of α-syn oligomers in spiked human saliva samples. According to the obtained results, this sensing platform has a good performance for α-syn oligomer detection and it can be considered as a promising candidate for the early diagnosis of PD.

Development of Nanomaterial-Modified Impedimetric Aptasensor—A Single-Step Strategy for 3,4-Methylenedioxymethylamphetamine Detection

Developing rapid, sensitive detection methods for 3,4-Methylenedioxymethylamphetamine (MDMA) is crucial to reduce its current misuse in the world population. With that aim, we developed an aptamer-modified tin nanoparticle (SnNP)-based nanoarchitecture as an electrochemical sensor in this study. This platform exhibited a high electron transfer rate with enhanced conductivity arising from its large surface area in comparison to the bare electrode. This observation was explained by the 40-fold higher electroactive surface area of SnNPs@Au, which provided a large space for 1.0 μM Apt_MDMA (0.68 ± 0.36 × 10¹² molecule/cm²) immobilization and yielded a significant electrochemical response in the presence of MDMA. Furthermore, the Apt_MDMA-modified SnNPs@Au sensing platform proved to be a simple yet ultrasensitive analytical device for MDMA detection in spiked biological and water samples. This novel electrochemical aptasensor showed good linearity in the range of 0.01–1.0 nM for MDMA (R² = 0.97) with a limit of detection of 0.33 nM and a sensitivity of 0.54 ohm/nM. In addition, the device showed high accuracy and stability along with signal recoveries in the range of 92–96.7% (Relative Standard Deviation, RSD, 1.1–2.18%). In conclusion, the proposed aptasensor developed here is the first to combine SnNPs and aptamers for illicit compound detection, and it offers a reliable platform for recreational drug detection.

Current Progress in Aptasensor for Ultra-Low Level Monitoring of Parkinson's Disease Biomarkers

In today's world, Parkinson's disease (PD) has been introduced as a long-term degenerative disorder of the central nervous system which mainly affects approximately more than ten million people worldwide. The vast majority of diagnostic methods for PD have operated based on conventional sensing platforms, while the traditional laboratory tests are not efficient for diagnosis of PD in the early stage due to symptoms of this common neurodegenerative syndrome starting slowly. The advent of the aptasensor has revolutionized the early-stage diagnosis of PD by measuring related biomarkers due to the myriad advantages of originating from aptamers which can be able to sensitive and selective capture various types of related biomarkers. The progress of numerous sensing platforms and methodologies in terms of biosensors based on aptamer application for PD diagnosis has revealed promising results. In this review, we present the latest developments in myriad types of aptasensors for the determination of related PD biomarkers. Working strategies, advantages and limitations of these sensing approaches are also mentioned, followed by prospects and challenges.

Aptamers Targeting Hallmark Proteins of Neurodegeneration

Neurodegeneration is a progressive deterioration of neural structures leading to cognitive or motor impairment of the affected patient. There is still no effective therapy for any of the most common neurodegenerative diseases (NDs) such as Alzheimer's or Parkinson's disease. Although NDs exhibit distinct clinical characteristics, many are characterized by the accumulation of misfolded proteins or peptide fragments in the brain and/or spinal cord. The presence of similar inclusion bodies in patients with diverse NDs provides a rationale for developing therapies directed at overlapping disease mechanisms. A novel targeting strategy involves the use of aptamers for therapeutic development. Aptamers are short nucleic acid ligands able to recognize molecular targets with high specificity and high affinity. Despite the fact that several academic groups have shown that aptamers have the potential to be used in therapeutic and diagnostic applications, their clinical translation is still limited. In this study, we describe aptamers that have been developed against proteins relevant to NDs, including prion protein and amyloid beta (Aβ), cell surface receptors and other cytoplasmic proteins. This review also describes advances in the application of these aptamers in imaging, protein detection, and protein quantification, and it provides insights about their accelerated clinical use for disease diagnosis and therapy.

Ultra-sensitive detection of florfenicol by flow injection chemiluminescence immunoassay based on Nickel/Cobalt bimetallic metal-organic framework nanozymes

The emergence and progress of metal-organic frameworks (MOFs) with high stability, large surface area, and abundant unsaturated active sites, once again promote the development of nanozymes, making nanozymes more advantageous to replace natural enzymes and will increase the applications of chemiluminescence immunoassay. In this study, a flow injection chemiluminescence immunoassay based on Ni/Co metal-organic framework (Ni/Co-MOF) nanozymes was developed, which can quickly and highly sensitively detect florfenicol (FF) in animal-derived food residues. Ni/Co-MOF_0.75 nanospheres can not only form stable immune probes with antibodies but also act as nanozymes to efficiently catalyze H₂O₂ for amplifying the chemiluminescence signal of the luminol-H₂O₂ system. In addition, due to good biocompatibility and large specific surface area, carboxyl-modified resin beads are used as a suitable material for loading more coating antigens. Based on the principle of competitive immunity, FF standard solution will compete with coating antigen loaded on the carboxyl resin beads for the limited binding sites on the FF antibody. Under the best experimental conditions, the detection range of FF is 0.0001-1000 ng mL^-1, and the detection limit (LOD) is 0.033 pg mL^-1 (S/N = 3). Furthermore, this method has been successfully applied to the analysis of actual samples with satisfactory results, which will provide a certain reference for the detection of small molecules in food and environmental analysis.

α-Synuclein in Parkinson's disease and advances in detection

Parkinson's disease (PD) is a threatening neurodegenerative disorder that seriously affects patients' life quality. Substantial evidence links the overexpression and abnormal aggregation of alpha-synuclein (α-Syn) to PD. α-Syn has been identified as a characteristic biomarker of PD, which indicates its great value of diagnosis and designing effective therapeutic strategy. This article systematically summarizes the pathogenic process of α-Syn based on recent researches, outlines and compares commonly used analysis and detection technologies of α-Syn. Specifically, the detection of α-Syn by new electrochemical, photochemical, and crystal biosensors is mainly examined. Furthermore, the speculation of future study orientation is discussed, which provides reference for the further research and application of α-Syn as biomarker.

Recent advances in metal/covalent organic framework-based electrochemical aptasensors for biosensing applications

The booming development of novel porous materials, metal-organic frameworks (MOFs) and covalent-organic frameworks (COFs) has been attracting a lot of attention due to their designabilities, diversities, and extensive applications. MOFs and COFs provide a new potential opportunity and platform to fabricate electrochemical aptasensors for biosensing applications. Compared to other traditional materials, MOF/COF-based electrochemical biosensors can appreciably amplify the electrochemical response signals to improve the sensing performance. Herein, we provide a comprehensive overview of MOF/COF-based electrochemical aptasensors for monitoring different ultra-trace analytes (e.g. antibiotics, pesticides, and cancer markers). This review systematically discusses the classification of electrochemical aptasensors based on various functional materials, including pure MOFs, MOF/conductive composites, metal nanoparticle/MOF composites, pure COFs, COFs/conductive composites, and other hybrid materials. Furthermore, some typical MOF/COF-based electrochemical aptasensors in the recognition of specific targets are described in detail to improve and guide further research for biosensing applications.

Aptamer-functionalized metal-organic frameworks (MOFs) for biosensing

As a class of crystalline porous materials, metal-organic frameworks (MOFs) have attracted increasing attention. Due to the nanoscale framework structure, adjustable pore size, large specific surface area, and good chemical stability, MOFs have been applied widely in many fields such as biosensors, biomedicine, electrocatalysis, energy storage and conversions. Especially when they are combined with aptamer functionalization, MOFs can be utilized to construct high-performance biosensors for numerous applications ranging from medical diagnostics and food safety inspection, to environmental surveillance. Herein, this article reviews recent innovations of aptamer-functionalized MOFs-based biosensors and their bio-applications. We first briefly introduce different functionalization methods of MOFs with aptamers, which provide a foundation for the construction of MOFs-based aptasensors. Then, we comprehensively summarize different types of MOFs-based aptasensors and their applications, in which MOFs serve as either signal probes or signal probe carriers for optical, electrochemical, and photoelectrochemical detection, with an emphasis on the former. Given recent substantial research interests in stimuli-responsive materials and the microfluidic lab-on-a-chip technology, we also present the stimuli-responsive aptamer-functionalized MOFs for sensing, followed by a brief overview on the integration of MOFs on microfluidic devices. Current limitations and prospective trends of MOFs-based biosensors are discussed at the end.

A highly-enhanced electrochemiluminescence luminophore generated by a metal-organic framework-linked perylene derivative and its application for ractopamine assay

In this study, a sensitive and effective monitoring method for ractopamine (RAC) was developed based on a sensitive electrochemiluminescence (ECL) aptasensor. Here, we employed a perylene derivative (PTC-PEI) with a Cu-based metal-organic framework (HKUST-1), which could accelerate the electron-transfer (ET) rate and strengthen interactions by the amido bond, resulting in enhanced ECL sensitivity and stability. Astonishingly, compared with the response of PTC-PEI and complex, the ECL signal of the MOF-based ECL material was noticeably raised by 6 times higher than that of PTC-PEI. HKUST-1 exhibited an excellent catalytic effect towards the electrochemical reduction process of S₂O₈^2-, thus allowing more sulfate radical anions (SO₄˙^-) to be generated. The strong ECL intensity of HKUST-1/PTC-PEI not only stemmed from the fixation of PTC-PEI that utilized its excellent film-forming abilities but also originated from the high porosity of HKUST-1 that carried more luminophores able to be excited. Satisfyingly, in the presence of the target molecule RAC, we observed an obvious quenching effect of signal, which could be attributed to aptamer recognition resulting in RAC being specifically captured on the electrode. Under optimal conditions, the developed sensor for the RAC assay displayed a desired linear range of 1.0 × 10^-12-1.0 × 10^-6 M and a low detection limit of 6.17 × 10^-13 M (S/N = 3). This ECL sensor showed high sensitivity, good stability and excellent selectivity. More importantly, the proposed aptasensor exhibited excellent determination towards RAC detection and potential practical utility for real samples.

Recent Advances in Aptamer Sensors

Recently, aptamers have attracted attention in the biosensing field as signal recognition elements because of their high binding affinity toward specific targets such as proteins, cells, small molecules, and even metal ions, antibodies for which are difficult to obtain. Aptamers are single oligonucleotides generated by in vitro selection mechanisms via the systematic evolution of ligand exponential enrichment (SELEX) process. In addition to their high binding affinity, aptamers can be easily functionalized and engineered, providing several signaling modes such as colorimetric, fluorometric, and electrochemical, in what are known as aptasensors. In this review, recent advances in aptasensors as powerful biosensor probes that could be used in different fields, including environmental monitoring, clinical diagnosis, and drug monitoring, are described. Advances in aptamer-based colorimetric, fluorometric, and electrochemical aptasensing with their advantages and disadvantages are summarized and critically discussed. Additionally, future prospects are pointed out to facilitate the development of aptasensor technology for different targets.